RPG Life Sciences Limited

Equities

RPGLIFE

INE105J01010

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:48 2024-04-26 am EDT 5-day change 1st Jan Change
1,567 INR +1.20% Intraday chart for RPG Life Sciences Limited +5.08% +17.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
RPG Life Sciences Limited Receives an Order from GST Authority, Jaipur, Rajasthan CI
RPG Life Sciences to Acquire 26% Stake in Sunpound Solar MT
Sunpound Solar Private Limited announced that it expects to receive INR 11 million in funding from RPG Life Sciences Limited CI
ICRA Lifts Rating on RPG Life Sciences' Long-term Financing to A+; Shares Jump 3% MT
RPG Life Sciences Limited Announces Order Passed by the Deputy Commissioner of State Tax CI
RPG Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : RPG Life Sciences Limited, Q2 2024 Earnings Call, Oct 19, 2023
RPG Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
RPG Life Sciences Limited Approves Dividend for the Financial Year Ended March 31, 2023 CI
RPG Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
RPG Life Sciences Limited Recommends Payment of Final Dividend for the Financial Year 2022-23 CI
RPG Life Sciences Seeks M&A CI
Transcript : RPG Life Sciences Limited, Q4 2023 Earnings Call, May 02, 2023
RPG Life Sciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
RPG Life Sciences Limited Recommends Dividend for the Year Ended March 31, 2023 CI
RPG Life Sciences Clocks Gains in Fiscal Q3 Net Profit MT
RPG Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Chart RPG Life Sciences Limited
More charts
RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The international formulations business is involved in developing, manufacturing and marketing oral solid formulations in the generic and branded generic space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Sodium Valproate PR, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, and others.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. RPGLIFE Stock
  4. News RPG Life Sciences Limited
  5. ICRA Lifts Rating on RPG Life Sciences' Long-term Financing to A+; Shares Jump 3%